Management of Metastatic Castration-Resistant Prostate Cancer

Presented by:
Sandy Srinivas
Search for other papers by Sandy Srinivas in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

Notable developments in the management of metastatic castration-resistant prostate cancer (mCRPC) include newer, more sophisticated imaging methods based on prostate-specific membrane antigen (PSMA) PET and development of radionuclide ligands for use with this modality. In the therapeutic area, PSMA PET–guided therapeutics are under study, and PARP inhibitors are being used to treat patients with gene alterations directly or indirectly involved with the homologous recombination repair pathway. Cabazitaxel has emerged as an effective third-line option for patients treated with prior novel hormonal agents and/or prior docetaxel. As investigators learn more about sequencing therapies for mCRPC, previous exposure is an important consideration for choice of treatment at disease progression.

Disclosures: Dr. Srinivas has disclosed receiving grant/research support from Endocyte and Exelixis Inc., and Bayer HealthCare; and serving as a scientific advisor for Bayer HealthCare.

Correspondence: Sandy Srinivas, MD, Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305. Email: sandysri@stanford.edu
  • Collapse
  • Expand
  • 1.

    Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A 2005;102:59815986.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Eder M, Schäfer M, Bauder-Wüst U et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012;23:688697.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Barinka C, Byun Y, Dusich CL, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem 2008;51:77377743.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Pienta KS, Gorin MA, Rowe SP. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate-specific membrane antigen PET/CT with 18 F-DCFPyL in prostate cancer patients (OSPREY) [published online February 26, 2021]. J Urol, doi: 10.1097/JU.0000000000001698

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Fendler W, Weber M, Iravani A, et al. Prostate-specific membrane antigen ligand positron emission tomography in met with non-metastatic castration-resistant prostate cancer. Clin Cancer Res 2019;25:74487434.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Crawford ED, Schellhammer PF, McLeod DG, et al. Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. J Urol 2018;200:956966.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020;383:23452357.

  • 8.

    deBono J, Mateo J, Fizazi K, et al. Olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020;382:20912102.

  • 9.

    Abida A, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 alteration. J Clin Oncol 2020;38:37633772.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2021. Accessed April 1, 2021. To view the most recent version, visit NCCN.org

    • PubMed
    • Export Citation
  • 11.

    DeWit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in prostate cancer. N Engl J Med 2019;381:25062518.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2004 624 23
PDF Downloads 1290 216 6
EPUB Downloads 0 0 0